Year All20232022 08/31/2023 Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference 08/10/2023 Third Harmonic Bio Announces Second Quarter 2023 Financial Results 07/25/2023 Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 05/11/2023 Third Harmonic Bio Announces First Quarter 2023 Financial Results 03/29/2023 Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results 12/15/2022 Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria 11/21/2022 Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference 11/09/2022 Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update 09/19/2022 Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares 09/14/2022 Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering
12/15/2022 Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
11/21/2022 Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
11/09/2022 Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
09/19/2022 Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
